References
- Heinzerling, L.M., Dummer, R., Kempf, W., Schmid, M.H. and Burg, G. (2000) "Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma", Arch. Dermatol., 136, 374— 378.
- Gellrich, S., Muche, J.M., Pelzer, K., Audring, H. and Sterry, W. (2001) "Anti-CD20 antibodies in primary cutaneous B-cell lympho-mas. Initial results in dermatologic patients", Hautarzt, 52, 205–210.
- Winkler, U., Jensen, M., Manzke, 0., Schulz, H., Diehl, V. and Engert, A. (1999) "Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab IDEC-C2B8)", Blood, 94, 2217 — 2224.
- Bienvenu, J., Chvetzoff, R., Salles, G., Balter, C., Tilly, H., Herbrecht, R., et al. (2001) "Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment", Hematol. J., 2, 378 — 384.
- van der Kolk, L.E., Grillo-Lopez, A.J., Baars, J.W., Hack, C.E. and van Oers, M.H. (2001) "Complement activation plays a key role in the side-effects of rituximab treatment", Br. J. Haematol., 115, 807 — 811.